Enliven Therapeutics Q1 2021 Earnings Report
Key Takeaways
Imara Inc. reported its financial results for the first quarter of 2021. They reported a net loss attributable to common stockholders of $10.3 million, or $0.58 per share. As of March 31, 2021, cash, cash equivalents and investments were $75.6 million.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021
Completed enrollment in the transfusion-dependent beta-thalassemia arm of the Forte Phase 2b trial
Higher dose arms open in both the Ardent and Forte Phase 2b clinical trials
Applications now being accepted for 2021 Real Impact grant program
Enliven Therapeutics
Enliven Therapeutics
Forward Guidance
Imara provided financial guidance for the full year 2021 and expects that its cash, cash equivalents and investments as of March 31, 2021, will be sufficient to enable it to fund its planned operations into mid-2022.
Positive Outlook
- Full-year 2021 research and development expenses will range between $50 million and $55 million
- Full-year 2021 general and administrative expenses will range between $12 million and $14 million.
- Cash, cash equivalents and investments as of March 31, 2021, will be sufficient to enable it to fund its planned operations into mid-2022.